Spectrum to re-submit Fusilev for colorectal cancer in the US
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals has met the US FDA to discuss the complete response letter it received for the NDA for its injectable chemotherapy drug Fusilev (levoleucovorin) for advanced metastatic colorectal cancer. The company said it would be able to respond to the agency's requests by the end of the third quarter of this year.